Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
Healthcare
$40.49 +5.07%
+$2.47 today
- Market cap
- $116.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
52W Low $7.00High $838.13
Volume 0.05M
Average 0.06M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$33.33M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$43.48M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.96M | 3.63M | 4.62M | 5.35M | 2.57M |
| Change in Working Capital | 1.96M | 1.13M | 10.36M | (8.57M) | (724K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (805K) | (1.4M) | 1.91M | (2.04M) | (352K) |
| Other Working Capital | 2.76M | 2.53M | 8.45M | (6.53M) | (372K) |
| Other Non-Cash Items | 434K | (340K) | (404K) | 249K | 3.77M |
| Operating Cash Flow | (35.88M) | (41.68M) | (33.28M) | (55.96M) | (33.33M) |
| Capital Expenditures | (93K) | (8K) | (7K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (79.08M) | (36.8M) | (11.88M) | 0 | 0 |
| Sales of Investments | 0 | 60.5M | 67.67M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (79.17M) | 23.69M | 55.78M | 0 | 0 |
| Debt Repayment | 220K | 0 | (1.62M) | (1.62M) | (2.06M) |
| Common Stock Issued | 0 | (201K) | 53.62M | 246K | 50M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 423K | (40K) | (2.85M) | (246K) | (4.53M) |
| Financing Cash Flow | 643K | (241K) | 49.14M | (1.62M) | 43.48M |
| Effect of Forex Changes | 0 | 187K | 0 | 0 | 0 |
| Net Change in Cash | (114.4M) | (18.05M) | 71.64M | (57.59M) | 10.15M |
| Free Cash Flow | (35.97M) | (41.69M) | (33.28M) | (55.96M) | (33.33M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.0M
+ D&A$21.0K
+ Stock-Based Comp$2.6M
+ Deferred Tax$0
- Working Capital-$724.0K
+ Other Non-Cash$3.8M
= Operating Cash Flow-$33.3M
- Capex$0
= Free Cash Flow-$33.3M
Analysis
FY2025 free cash flow is -$33.3M. FCF conversion is 85.5% of net income. Operating cash flow was -$33.3M, with capex of $0. The largest bridge item is Other Non-Cash at $3.8M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
Does SPRB generate free cash flow?
Spruce Biosciences, Inc. (SPRB) generated -$33.33M of free cash flow in fiscal 2025.
How much operating cash flow does SPRB produce?
Operating cash flow was -$33.33M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.